The state of Illinois currently has 15 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/19/2024
Locations: Local Institution - 0435, Chicago, Illinois +4 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
NCT05785624
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/17/2024
Locations: Northwestern Medicine - Northwestern Medicine Glen, Glenview, Illinois
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Register for Updates
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: UI Health Hospital, Chicago, Illinois
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
NCT05389215
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/16/2024
Locations: Loyola University Medical Center (LUMC), Maywood, Illinois
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/11/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
NCT01915511
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
04/09/2024
Locations: University of Chicago, Chicago, Illinois +2 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
NCT05483907
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/01/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois +5 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/01/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois +3 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: GenHarp Clinical Solutions, Chicago, Illinois
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
NCT00470327
Recruiting
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Register for Updates
Explanted Lung Tissues With Pulmonary Fibrosis
NCT00515567
Recruiting
The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: The University of Chicago, Chicago, Illinois
Conditions: Pulmonary Fibrosis
Register for Updates